Provided by Tiger Trade Technology Pte. Ltd.

Eupraxia Pharmaceuticals

7.46
-0.1100-1.45%
Post-market: 7.460.00000.00%16:10 EDT
Volume:1.05M
Turnover:7.89M
Market Cap:492.91M
PE:-7.48
High:7.70
Open:7.57
Low:7.28
Close:7.57
52wk High:9.32
52wk Low:5.25
Shares:66.07M
Float Shares:54.52M
Volume Ratio:0.80
T/O Rate:1.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9967
EPS(LYR):-1.0300
ROE:-66.70%
ROA:-43.66%
PB:4.84
PE(LYR):-7.24

Loading ...

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences

GlobeNewswire
·
Yesterday

Eupraxia Pharmaceuticals Down Nearly 11%, on Pace for Largest Percent Decrease Since September 2025

Dow Jones
·
Oct 02

Eupraxia Pharmaceuticals Price Target Maintained with a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 01

Eupraxia Pharmaceuticals Initiated at Outperform by Wedbush

Dow Jones
·
Sep 24

Eupraxia Pharmaceuticals Inc : Wedbush Initiates Coverage with Outperform Rating; Price Target $17

THOMSON REUTERS
·
Sep 24

Wedbush Initiates Eupraxia Pharmaceuticals at Outperform With $17 Price Target

MT Newswires Live
·
Sep 24

H.C. Wainwright Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)

TIPRANKS
·
Sep 22

Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences

GlobeNewswire
·
Sep 08

Eupraxia Pharmaceuticals management to meet with Oppenheimer

TIPRANKS
·
Sep 04

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients

GlobeNewswire
·
Aug 13

Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline

Benzinga Earnings
·
Aug 12

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

GlobeNewswire
·
Aug 12

Eupraxia Pharmaceuticals files $300M mixed securities shelf

TIPRANKS
·
Aug 06

David Martin Reiterates Buy on Eupraxia Pharmaceuticals, Citing Strong KOL Support for EP-104GI’s Commercialization Potential

TIPRANKS
·
Aug 03

Eupraxia Pharmaceuticals: Buy Rating Backed by EP-104GI’s Seamless Fit Into GI Practice and Strong Commercial Outlook

TIPRANKS
·
Jul 31

Top Premarket Decliners

MT Newswires Live
·
Jul 28

Buy Rating Reaffirmed on EPRX as EP-104GI Catalyst Nears and $16 Price Target Remains Unchanged

TIPRANKS
·
Jul 22

Cantor Fitzgerald Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)

TIPRANKS
·
Jul 20

Eupraxia Pharmaceuticals Overhauls Leadership and Operations Ahead of Key EoE Trial Milestone

TIPRANKS
·
Jul 14

Eupraxia chief scientific and operating officer Amanda Malone steps down

TIPRANKS
·
Jul 14